CD53 and breast carcinoma: The suggested predictive value of CD53 is supported by the finding that CD53−/− mice showed increased tumour growth with respect to wild type counterparts, by using syngeneic immunogenic tumour models [96] and, furthermore, CD53 network predicts distant metastasis-free survival, especially in ER− breast cancer [107].